Study of the efficacy of sucroferric oxyhydroxide (chewable tablet) on the control of CKD-MBD and improvement of renal anemia in hemodialysis patients with hyperphosphatemia.
Phase of Trial: Phase III
Latest Information Update: 22 Dec 2016
At a glance
- Drugs Sucroferric oxyhydroxide (Primary)
- Indications Hyperphosphataemia
- Focus Adverse reactions; Therapeutic Use
- 20 Dec 2016 Status changed from not yet recruiting to recruiting.
- 20 Aug 2016 New trial record